Franco Folli, MD

Department of Health Sciences, University of Milan, Milan, Italy

  • 5Articles
  • 24.9KReads1
  • 2023–2025Active
  • 27Collaborators
  • 31Citations2

About

Franco Folli, MD, is affiliated with the Department of Health Sciences at the University of Milan, Italy. Folli has published extensively on the use of esmethadone (REL-1017) in the treatment of major depressive disorder (MDD), focusing on its efficacy, safety, and therapeutic response, including in patients with antidepressant tachyphylaxis and inadequate response to standard treatments. The research also explores cognitive measures and long-term outcomes related to esmethadone in MDD. Collaborators frequently include Andrea Mattarei, Clotilde Guidetti, Luca Pani, Marco Pappagallo, and Maurizio Fava.

Publications

JCP
Esmethadone (REL-1017) in Patients with Major Depressive Disorder and Antidepressant Tachyphylaxis
Original Research

Esmethadone (REL-1017) in Patients with Major Depressive Disorder and Antidepressant Tachyphylaxis

October 6, 2025

Esmethadone may be a potentially safe and effective adjunctive treatment for patients with MDD and antidepressant tachyphylaxis.
, , , et al
JCP
Long-Term Safety and Efficacy of Esmethadone in MDD
Original Research

Long-Term Safety and Efficacy of Esmethadone in MDD

February 17, 2025

A durable improvement in MDD symptoms for up to 1 year was observed with esmethadone with high rates of response and remission.
, , , et al
JCP
Esmethadone in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants
Original Research

Esmethadone in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants

June 17, 2024

Although this trial of esmethadone did not meet its primary outcome, some secondary and post hoc outcomes were promising.
, , , et al
JCP
Effect of Time From Onset of MDD on Response to Esmethadone
Original Research

Effect of Time From Onset of MDD on Response to Esmethadone

May 13, 2024

Esmethadone 25 and 50 mg were more effective in reducing depression scale scores in patients who had a shorter time since their first major depressive episode.
, , , et al
PCC
REL-1017 Effects on Cognition in MDD
Original Research

REL-1017 Effects on Cognition in MDD

February 14, 2023

REL-1017 improved subjective measures of cognitive impairment, in addition to improving total MADRS and SDQ scores.
, , , et al

1 Read counts for articles published before 2020 may include some non-human traffic.

2 Citation counts provided by Crossref.

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Ketamine and Psychedelics

Listen to the Podcast
The Journal of Clinical Psychiatry podcast cover with Benjamin Brody, MD

Subscribe to read
more articles

Subscribe